169 related articles for article (PubMed ID: 36752970)
1. Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients.
Helvind NM; Weitemeyer MB; Chakera AH; Hendel HW; Ellebæk E; Svane IM; Kjærskov MW; Bojesen S; Skyum H; Petersen SK; Bastholt L; Johansen C; Bidstrup PE; Hölmich LR
Ann Surg Oncol; 2023 Apr; 30(4):2377-2388. PubMed ID: 36752970
[TBL] [Abstract][Full Text] [Related]
2.
Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
[TBL] [Abstract][Full Text] [Related]
3. Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic stage IIB-III melanoma patients.
Helvind NM; Aros Mardones CA; Hölmich LR; Hendel HW; Bidstrup PE; Sørensen JA; Chakera AH
Eur J Surg Oncol; 2021 Dec; 47(12):3020-3027. PubMed ID: 34120809
[TBL] [Abstract][Full Text] [Related]
4. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Prognostic Value of
Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
[TBL] [Abstract][Full Text] [Related]
6.
Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
[TBL] [Abstract][Full Text] [Related]
7. Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021: A National Observational Cohort Study of 25 720 Patients With Stage IA to IV Melanoma.
Helvind NM; Brinch-Møller Weitemeyer M; Chakera AH; Hendel HW; Ellebæk E; Svane IM; Kjærskov MW; Bojesen S; Skyum H; Petersen SK; Bastholt L; Johansen C; Bidstrup PE; Hölmich LR
JAMA Dermatol; 2023 Nov; 159(11):1213-1222. PubMed ID: 37650576
[TBL] [Abstract][Full Text] [Related]
8. The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma.
Stahlie EHA; van der Hiel B; Stokkel MPM; Schrage YM; van Houdt WJ; Wouters MW; van Akkooi ACJ
J Surg Oncol; 2020 Dec; 122(7):1328-1336. PubMed ID: 32783266
[TBL] [Abstract][Full Text] [Related]
9. Restaging [
Mahajan S; Barker CA; Mauguen A; Singh B; Pandit-Taskar N
J Am Acad Dermatol; 2020 Apr; 82(4):878-886. PubMed ID: 31562942
[TBL] [Abstract][Full Text] [Related]
10. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
Abbott RA; Acland KM; Harries M; O'Doherty M
Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913
[TBL] [Abstract][Full Text] [Related]
11. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
[TBL] [Abstract][Full Text] [Related]
12. Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study.
Kaumanns A; König D; Hojski A; Cattaneo M; Chirindel A; Wiese M; Tamm M; Lardinois D; Rothschild SI
Lung Cancer; 2022 Nov; 173():14-20. PubMed ID: 36108578
[TBL] [Abstract][Full Text] [Related]
13. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma
Koskivuo I; Kemppainen J; Giordano S; Seppänen M; Veräjänkorva E; Vihinen P; Minn H
Acta Oncol; 2016 Nov; 55(11):1355-1359. PubMed ID: 27553064
[TBL] [Abstract][Full Text] [Related]
14. The value of lymph node ultrasound and whole body
Stahlie EHA; van der Hiel B; Bruining A; van de Wiel B; Schrage YM; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
Eur J Surg Oncol; 2021 May; 47(5):1157-1162. PubMed ID: 33353826
[TBL] [Abstract][Full Text] [Related]
15. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
Lee JW; Nam SB; Kim SJ
Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of positron emission tomography in the management of cutaneous melanoma.
Friedman KP; Wahl RL
Semin Nucl Med; 2004 Oct; 34(4):242-53. PubMed ID: 15493002
[TBL] [Abstract][Full Text] [Related]
17. FDG PET in early stage cutaneous malignant melanoma.
McIvor J; Siew T; Campbell A; McCarthy M
J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
[TBL] [Abstract][Full Text] [Related]
18. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Melanoma and Skin Malignancies.
Lee ST; Kovaleva N; Senko C; Kee D; Scott AM
PET Clin; 2024 Apr; 19(2):231-248. PubMed ID: 38233284
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma.
Andersen JAS; Spatzek AD; Vilstrup MH; Grupe P; Hess S; Holdgaard PC; Bastholt L; Gerke O; Hildebrandt MG
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2342-2351. PubMed ID: 35129651
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma.
Dieng M; Lord SJ; Turner RM; Nieweg OE; Menzies AM; Saw RPM; Einstein AJ; Emmett L; Thompson JF; Lo SN; Morton RL
Ann Surg Oncol; 2022 May; 29(5):2871-2881. PubMed ID: 35142966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
